Contact Us | 1-800-343-7475
Accelerating Protein Analysis Throughput at Boehringer Ingelheim
Unlike traditional drug discovery, which focuses on inhibiting or activating proteins, targeted protein degradation (TPD) offers a more precise and efficient way to alter cellular pathways. However, TDP faces several challenges that need to be overcome to reach its full potential, with reducing the bottleneck of quantitative protein analysis one of these.
In this webinar, the team at Boehringer Ingelheim present their recent real-world TPD project examples and in-depth analysis, covering insights on device and consumable management and optimized assay setups to increase protein analysis throughput.
Key Takeaways:
Andrea began her journey as a master's student at Boehringer Ingelheim's department of Cancer Cell Signaling in 2020. After completing her master's degree, she continued at BI as a lab scientist, focused on validating novel targets and innovative techniques. |
After a master's in molecular biology at the University of Vienna, Johannes joined Boehringer Ingelheim full time, focusing first on immune oncology, then cancer research leveraging platforms for automated protein analysis. |
Teresa finished her master's thesis at Boehringer Ingelheim before traveling south-east Asia. On return, she rejoined BI full-time to focus on protein analysis for drug development for the last five years. She is dedicated to improving research efficiency through use of novel platforms. |